Ciftel, S. Et Al. 2025. Cardiometabolic risk in non-diabetic metabolic dysfunction-associated steatotic liver disease (MAFLD) patients: insights from the triglyceride-glucose, plasma atherogenic, and cardiometabolic index. Archives of Medical Science , vol.21, no.2 , 401-408.

Ciftel, S., Çiftel, S., Baykan, A. R., Cerrah, S., Çiftel, E., & MERCANTEPE, F., (2025). Cardiometabolic risk in non-diabetic metabolic dysfunction-associated steatotic liver disease (MAFLD) patients: insights from the triglyceride-glucose, plasma atherogenic, and cardiometabolic index. Archives of Medical Science , vol.21, no.2, 401-408.

Ciftel, Sedat Et Al. "Cardiometabolic risk in non-diabetic metabolic dysfunction-associated steatotic liver disease (MAFLD) patients: insights from the triglyceride-glucose, plasma atherogenic, and cardiometabolic index," Archives of Medical Science , vol.21, no.2, 401-408, 2025

Ciftel, Sedat Et Al. "Cardiometabolic risk in non-diabetic metabolic dysfunction-associated steatotic liver disease (MAFLD) patients: insights from the triglyceride-glucose, plasma atherogenic, and cardiometabolic index." Archives of Medical Science , vol.21, no.2, pp.401-408, 2025

Ciftel, S. Et Al. (2025) . "Cardiometabolic risk in non-diabetic metabolic dysfunction-associated steatotic liver disease (MAFLD) patients: insights from the triglyceride-glucose, plasma atherogenic, and cardiometabolic index." Archives of Medical Science , vol.21, no.2, pp.401-408.

@article{article, author={Sedat Ciftel Et Al. }, title={Cardiometabolic risk in non-diabetic metabolic dysfunction-associated steatotic liver disease (MAFLD) patients: insights from the triglyceride-glucose, plasma atherogenic, and cardiometabolic index}, journal={Archives of Medical Science}, year=2025, pages={401-408} }